Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Demyelination
ADR ID BADD_A01194
ADR Hierarchy
17      Nervous system disorders
17.16      Demyelinating disorders
17.16.02      Demyelinating disorders NEC
17.16.02.001      Demyelination
Description Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system. | The first region-restricted episode of CNS inflammatory demyelination in a patient. It is usually characterized by an acute monosymptomatic presentation of the optic nerves, brainstem, or spinal cord. It may not reoccur (isolated), or it may progress to MULTIPLE SCLEROSIS. [MeSH]
MedDRA Code 10012305
MeSH ID D003711
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Cord demyelinating disorder | Cord demyelinating disorder NOS | Demyelinating disease (excl multiple sclerosis) | Demyelinating disease of central nervous system, unspecified | Demyelination | Demyelination NOS | Other demyelinating diseases of central nervous system | Other specified demyelinating diseases of central nervous system | Demyelination disorder NOS | Myelinolysis | White matter demyelination | Gray matter demyelination | Grey matter demyelination | Demyelinating Diseases | Demyelinating Disease | Demyelinating Disorders | Demyelinating Disorder | Demyelinations | Clinically Isolated Syndrome, CNS Demyelinating | Clinically Isolated CNS Demyelinating Syndrome
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01834Prednisone--
BADD_D02100Sunitinib0.000112%
BADD_D02105Tacrolimus0.001040%
BADD_D02150Temozolomide0.000112%
BADD_D02165Teriflunomide0.000844%
BADD_D02192Thalidomide--
BADD_D02236Tofacitinib0.001085%
BADD_D02246Tolvaptan0.000087%
BADD_D02247Topiramate0.000075%
BADD_D02375Water--
BADD_D02407Upadacitinib0.000482%
BADD_D02464Fingolimod0.004099%
BADD_D02473Sodium chloride0.000362%
The 2th Page    First    Pre   2    Total 2 Pages